Unified applications for clinical, regulatory, and quality help fast-growing start-up drive greater efficiency and compliance throughout development<\/em><\/p>\n BARCELONA, Spain \u2014 10 July 2018 \u2014 <\/strong> Veeva Systems<\/a> (NYSE:VEEV) today announced that Idorsia Pharmaceuticals Ltd established an integrated development landscape with Veeva Development Cloud<\/a>. With unified applications for clinical, regulatory, and quality on a single cloud platform, Idorsia now has the technology foundation to accelerate product innovation and support its global growth plans.<\/p>\n \u201cWith a strong pipeline of innovative new therapies, we needed cutting-edge cloud technology that could scale as we grow,\u201d said Joseph Bejjani, CIO at Idorsia. \u201cOur IT strategy had three guiding principles when it came to product selection \u2013 cloud-first, easy-to-use functionality, and integrated, platform-based solutions. Veeva met all three objectives within a very tight timeline.\u201d<\/p>\n Idorsia is a fast-growing biopharmaceutical start-up focused on research and early-stage clinical development. Immediately after its founding, Idorsia set an aggressive timeline to transition to new clinical development systems within 12 months.<\/p>\n With Veeva Development Cloud, Idorsia has unified applications to streamline documents and workflows so teams have a single source of truth across clinical, regulatory, and quality. This eliminates manual, duplicative efforts and gives teams consistent information throughout clinical development. Because Veeva Vault applications have the same modern and intuitive interface, teams work with greater speed and spend less time on training.<\/p>\n \u201cVeeva gives us the right technology foundation to manage business processes, content, and data across the organization,\u201d said Simone Mechler, associate director clinical & quality systems. \u201cWe exceeded our goal and went live within seven months. All regions and departments now have a consistent view of the products in development to drive greater operational efficiency and maintain compliance.\u201d<\/p>\n Idorsia is using or plans to use multiple applications across Veeva Development Cloud suites, including Vault eTMF<\/a> and Vault CTMS<\/a> from Vault Clinical Suite<\/a>; Vault Registrations<\/a>, Vault Submissions<\/a>, and Vault Submissions Publishing<\/a> from Vault RIM Suite<\/a>; and Vault QMS<\/a> and Vault QualityDocs<\/a> from Vault Quality Suite<\/a>.<\/p>\n \u201cIdorsia needed to bring together their applications for clinical, quality, and regulatory to streamline drug development,\u201d said Rik Van Mol, vice president, R&D strategy, Europe at Veeva. \u201cVeeva Development Cloud helps life sciences companies like Idorsia achieve alignment across headquarters, sites, and countries and increases communication, collaboration, and compliance across the functions.\u201d<\/p>\n Additional Information<\/strong> About Veeva Systems<\/strong> Forward-looking Statements<\/strong> ###<\/p>\n Contact:<\/strong> Idorsia drives efficient, compliant development with unified clinical, regulatory, and quality applications.<\/p>\n","protected":false},"featured_media":20377,"parent":0,"template":"","class_list":["post-20371","resources","type-resources","status-publish","has-post-thumbnail","hentry","resource-area-20-clinical-data-management","resource-area-20-clinical-operations","resource-area-20-development-cloud-a","resource-area-20-quality","resource-area-20-regulatory","resource-area-20-research-sites","resource-area-20-safety","resource-product-20-batch-release","resource-product-20-ctms","resource-product-20-development-cloud","resource-product-20-disclosures","resource-product-20-dqs","resource-product-20-epro","resource-product-20-edc","resource-product-20-eisf","resource-product-20-esource","resource-product-20-etmf","resource-product-20-vault-lims","resource-product-20-vault-medcomms","resource-product-20-medical-insights","resource-product-20-vault-medinquiry","resource-product-20-payments","resource-product-20-postmarket-surveillance","resource-product-20-publications","resource-product-20-qms","resource-product-20-qualitydocs","resource-product-20-reference-data-opendata-clinical","resource-product-20-registrations","resource-product-20-rtsm","resource-product-20-safety2","resource-product-20-safety-content","resource-product-20-safety-signal","resource-product-20-safety-workbench","resource-product-20-site-connect","resource-product-20-sponsor-site-collaboration","resource-product-20-station-manager","resource-product-20-study-startup","resource-product-20-study-training","resource-product-20-submissions","resource-product-20-submissions-archive","resource-product-20-submissions-publishing","resource-product-20-training","resource-product-20-vault-validation-management","resource-type-news-press-release"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/20371"}],"collection":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources"}],"about":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/types\/resources"}],"version-history":[{"count":2,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/20371\/revisions"}],"predecessor-version":[{"id":86593,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/20371\/revisions\/86593"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/media\/20377"}],"wp:attachment":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/media?parent=20371"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nFor more on Veeva Development Cloud, visit: veeva.com\/VeevaDevelopmentCloud<\/a>
\nConnect with Veeva on LinkedIn: linkedin.com\/company\/veeva-systems<\/a>
\nFollow @Veeva_EU on Twitter: twitter.com\/veeva_eu <\/a>
\nLike Veeva on Facebook: facebook.com\/veevasystems<\/a><\/p>\n
\nVeeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 625 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit veeva.com\/eu<\/a>.<\/p>\n
\nThis release contains forward-looking statements, including the market demand for and acceptance of Veeva\u2019s products and services, the results from use of Veeva\u2019s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva\u2019s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva\u2019s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva\u2019s financial results are included under the captions, \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations,\u201d in the company\u2019s filing on Form 10-Q for the period ended April 30, 2018. This is available on the company\u2019s website at veeva.com<\/a> under the Investors section and on the SEC\u2019s website at sec.gov<\/a>. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.<\/p>\n
\nSue Glanville \/ Cate Bonthuys
\nVeeva Systems Inc.
\nsue@catalystcomms.co.uk<\/a> \/ cate@catalystcomms.co.uk<\/a>
\n+44 (0) 7715 817589 \/ +44 (0) 7746 546773<\/p>\n","protected":false},"excerpt":{"rendered":"